Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00840398 | Buspirone Hydrochloride 30mg Tablets, Non-Fasting | PHASE1 | COMPLETED | 24 | — | — | Dec 1, 2001 | Dec 1, 2001 | Aug 19, 2024 | 1 | United States |
| NCT00840606 | Buspirone Hydrochloride 30mg Tablets, Fasting | PHASE1 | COMPLETED | 70 | — | — | Dec 1, 2001 | Apr 1, 2002 | Aug 19, 2024 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BUSPAR® 30 mg Tablet | DRUG | 1 x 30 mg, single-dose fed |
| Buspirone Hydrochloride 30 mg Tablet | DRUG | 1 x 30 mg, single-dose fed |
Inclusion Criteria: * Screening Demographics: All volunteers selected for this study will be healthy men or women 18 years of age or older at the time of dosing. The volunteer's body mass index (BMI) is less than or equal to 30. * Screening Procedures: Each volunteer will complete the screening pro...